0001104659-26-037729
SEC filingTvardi Therapeutics reported narrower losses in FY2025 compared to the prior year, driven by reduced clinical trial activity and cost adjustments following the discontinuation of certain programs, though the company continues to operate without revenue and remains dependent on external financing.
The improvement in operating and net losses during FY2025 was primarily driven by reductions in research and development expenses tied to clinical trial activity. The decrease in costs related to the IPF trial resulted from lower patient enrollment as the study matured, along with revised estimates from clinical trial change orders. Additionally, the discontinuation of the mBC trial in January 2024 led to a significant reduction in associated expenses, with a true-up adjustment recorded in Q2 2025 following negotiations of wind-down costs.
Operating income increased by 54.2% year-over-year, moving from -$58.4M in FY2024 to -$26.7M in FY2025, while net income showed an even stronger improvement of 74.3%, narrowing from -$70.9M to -$18.2M. This disproportionate improvement reflects not only lower operating costs but also fewer non-operating charges compared to the prior year. Diluted EPS followed the same trend, improving from $-15.53 to $-3.26, signaling reduced per-share loss burden.
Net cash used in operating activities declined sharply to -$23.5M in FY2025 from -$60.9M in FY2024, consistent with reduced clinical spending. However, the company continues to generate no revenue from product sales or other sources and remains fully reliant on external capital. Liquidity is therefore contingent on future financing rounds, and management has indicated that failure to raise funds could necessitate delays, reductions, or termination of ongoing and planned clinical trials.
Despite near-term cost savings, the company expects research and development expenses to increase substantially going forward as it advances TTI-101 and TTI-109, supports preclinical programs, and expands headcount. Process development for commercial-scale drug production is underway, aiming for reproducible and cost-effective manufacturing. However, there is uncertainty around future collaborations and their potential impact on funding and development timelines. Absent new partnerships or financing, the current trajectory will require continued capital infusions to maintain operations.